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Abstract
Introduction Transforming growth factor (TGF)-β suppresses
breast cancer formation by preventing cell cycle progression in
mammary epithelial cells (MECs). During the course of
mammary tumorigenesis, genetic and epigenetic changes
negate the cytostatic actions of TGF-β, thus enabling TGF-β to
promote the acquisition and development of metastatic
phenotypes. The molecular mechanisms underlying this
conversion of TGF-β function remain poorly understood but may
involve signaling inputs from integrins.
Methods  β3  Integrin expression or function in MECs was
manipulated by retroviral transduction of active or inactive β3
integrins, or by transient transfection of small interfering RNA
(siRNA) against β3 integrin. Altered proliferation, invasion, and
epithelial-mesenchymal transition (EMT) stimulated by TGF-β in
control and β3 integrin manipulated MECs was determined. Src
involvement in β3  integrin mediated alterations in TGF-β
signaling was assessed by performing Src protein kinase
assays, and by interdicting Src function pharmacologically and
genetically.
Results TGF-β stimulation induced αvβ3 integrin expression in a
manner that coincided with EMT in MECs. Introduction of siRNA
against β3 integrin blocked its induction by TGF-β and prevented
TGF-β stimulation of EMT in MECs. β3  integrin interacted
physically with the TGF-β receptor (TβR) type II, thereby
enhancing TGF-β stimulation of mitogen-activated protein
kinases (MAPKs), and of Smad2/3-mediated gene transcription
in MECs. Formation of β3 integrin:TβR-II complexes blocked
TGF-β mediated growth arrest and increased TGF-β mediated
invasion and EMT. Dual β3 integrin:TβR-II activation induced
tyrosine phosphorylation of TβR-II, a phosphotransferase
reaction mediated by Src in vitro. Inhibiting Src activity in MECs
prevented the ability of β3 integrin to induce TβR-II tyrosine
phosphorylation, MAPK activation, and EMT stimulated by TGF-
β. Lastly, wild-type and D119A β3 integrin expression enhanced
and abolished, respectively, TGF-β stimulation of invasion in
human breast cancer cells.
Conclusion We show that β3 integrin alters TGF-β signaling in
MECs via Src-mediated TβR-II tyrosine phosphorylation, which
significantly enhanced the ability of TGF-β to induce EMT and
invasion. Our findings suggest that β3  integrin interdiction
strategies may represent an innovative approach to re-
establishing TGF-β mediated tumor suppression in progressing
human breast cancers.
Introduction
Transforming growth factor (TGF)-β is a powerful tumor sup-
pressor that prevents the uncontrolled proliferation of epithe-
lial, endothelial, and hematopoietic cells. In doing so, TGF-β
initiates transmembrane signaling by activating its type I and
type II serine/threonine kinase receptors (TGF-β receptor TβR-
ECM = extracellular matrix; EGF = epidermal growth factor; EMT = epithelial-mesenchymal transitions; ERK = extracellular signal-regulated kinase; 
FACS = fluorescence-activated cell sorter; FAK = focal adhesion kinase; FBS = fetal bovine serum; GFP = green fluorescent protein; GST = glu-
tathione S-transferase; IRES = internal ribosomal entry site; MAPK = mitogen-activated protein kinase; MEC = mammary epithelial cell; PBS = phos-
phate-buffered saline; PCR = polymerase chain reaction; PI3K = phosphoinositol-3 kinase; PMA = 4α-phorbol 12-myristate 13-acetate; pMSCV = 
plasmid murine stem cell virus; PTK = protein tyrosine kinase; RGD = arginine-glycine-aspartic acid; RTK = receptor tyrosine kinase; siRNA = small 
interfering RNA; TβR = TGF-β receptor; TGF = transforming growth factor; WT = wild type; YFP = yellow fluorescent protein.Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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I and TβR-II, respectively). Following its transphosphorylation
and stimulation by TβR-II, TβR-I then binds, phosphorylates,
and activates the intracellular effectors Smad2 and Smad3,
which subsequently complex with Smad4 and translocate to
the nucleus to regulate target gene transcription [1]. Although
the Smad pathway is by far the most characterized TGF-β acti-
vated pathway, TGF-β also governs cell physiology through
activation of mitogen-activated protein kinases (MAPKs;
including extracellular signal-regulated kinase [ERK]1/2, p38,
and c-Jun amino-terminal kinase) and of phosphoinositol-3
kinase (PI3K) [2-5]. Aberrant activation of MAPKs and PI3K
often is associated with cancer development in humans. Pre-
cisely how TGF-β activates these alternative pathways and
how these signals are integrated into the biology and pathol-
ogy of TGF-β remain to be elucidated fully [6].
TGF-β plays a dual role during mammary tumorigenesis [7-
10]. For instance, TGF-β normally prohibits mammary epithe-
lial cell (MEC) cell cycle progression, and consequently sup-
presses MEC tumorigenesis. However, during the course of
mammary tumorigenesis, TGF-β signaling becomes dysregu-
lated and uncoupled from regulation of cell cycle progression.
More importantly, altered TGF-β signaling actively contributes
to the acquisition and development of metastatic phenotypes,
in part through its ability to stimulate epithelial-mesenchymal
transitions (EMTs) in cancerous MECs [11]. Indeed, recent
evidence suggests that TGF-β suppresses tumorigenesis
largely via Smad2/3-mediated growth arrest [1,6,8,12,13],
whereas its ability to promote tumorigenesis and EMT occurs
via the integration of Smad2/3 signals with those arising in
response to activation of RhoA, MAPKs (e.g. ERK1/2 and p38
MAPK), and PI3K pathways [2,3,14-16]. Thus, breast cancer
cells have developed effective strategies for circumventing the
tumor suppressing activities of TGF-β, while simultaneously
selecting for, or even enhancing, its tumor promoting activities
[8,17].
Apart from playing a prominent role in preventing cell cycle
progression, TGF-β also is a major regulator of cell microenvi-
ronments and extracellular matrix (ECM) remodeling. TGF-β
alters cell microenvironments in part through its ability to
induce the expression of unique subsets of integrins as well as
that of their ECM ligands [18]. In doing so, TGF-β enables
malignant cells to undergo EMT and, consequently, to escape
their tissue of origin [11].
Integrins are heterodimeric transmembrane receptors that
bind ECM ligands and couple cells to their microenvironments
[19]. Most integrins initiate transmembrane signaling by acti-
vating focal adhesion kinase (FAK) and Src family kinases at
adhesive sites. FAK and Src further recruit and activate various
downstream effectors, such as PI3K and members of the Ras
and Rho families of small GTPases [20-22]. Integrins also
interact with and couple to receptor tyrosine kinases (RTKs) to
promote cell survival, proliferation, and migration in response
to soluble growth factors and cytokines [23,24]. One such
integrin, namely αvβ3, binds to arginine-glycine-aspartic acid
(RGD) amino acid containing components of the ECM, such
as vitronectin, fibronectin, and osteopontin, and mediates RTK
activation of MAPKs and cell invasion [23-25]. Similar to the
effects of tumorigenesis on TGF-β signaling, integrin expres-
sion is altered during tumorigenesis, including developing
tumors of the breast [26,27]. In particular, altered αvβ3 integrin
expression correlates with mammary tumorigenesis, particu-
larly the processes of breast cancer cell invasion and metasta-
sis [25,27-31], raising the possibility that differential integrin
expression may contribute to the tumor promoting activities of
TGF-β. Indeed, TGF-β stimulated EMT is abrogated by treat-
ments that inhibit MEC integrin adhesion, suggesting a need
for integrins in mediating TGF-β signaling [32,33].
To further investigate the role of altered integrin expression in
regulating the MEC response to TGF-β, we determined the
effects of β3 integrin expression on the ability of TGF-β to reg-
ulate NMuMG (normal murine mammary gland) cell prolifera-
tion, invasion, and EMT. We found that treatment of NMuMG
cells with TGF-β induced their expression of αvβ3 integrin, an
event that coincided with TGF-β stimulation of EMT. Accord-
ingly, β3 integrin deficiency abolished the ability of TGF-β to
induce EMT in MECs. Moreover, we found that β3 integrin
interacted physically with TβR-II at the cell surface, leading to
conversion of TGF-β from a suppressor of NMuMG cell
growth to a promoter of their invasiveness and EMT. Mecha-
nistically, activated β3 integrin recruited Src to β3 integrin:TβR-
II complexes, where it tyrosine phosphorylated TβR-II, leading
to enhanced activation of MAPKs and induction of EMT stim-
ulated by TGF-β. Importantly, abolishing Src activity or expres-
sion in NMuMG cells prevented β3 integrin-mediated tyrosine
phosphorylation of TβR-II and, consequently, EMT stimulated
by TGF-β. Finally, we found that the acquisition of a metastatic
phenotype in MCF10A derivatives, which serve as a model of
human breast cancer progression regulated by TGF-β [9],
coincided with upregulated β3 integrin and FAK expression.
Similar to its effects in NMuMG cells, β3 integrin expression
significantly enhanced TGF-β mediated stimulation of cell inva-
sion in benign MCF10A cells as well as in their highly meta-
static counterparts MCF10CA1a cells. Importantly, the
expression of D119A β3 integrin in these metastatic cells com-
pletely abolished the ability of TGF-β to induce MCF10CA1a
cell invasion.
Taken together, our findings identify a novel convergence
point in MECs that enables β3 integrins to override the tumor
suppressing activities of TGF-β, suggesting that integrin inter-
diction strategies may one day represent an innovative
approach to re-establishing TGF-β mediated tumor suppres-
sion in progressing human breast cancers.Available online http://breast-cancer-research.com/content/8/4/R42
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Materials and methods
Retroviral plasmids and expression
The cDNAs encoding wild-type (WT) human β3 integrin, as
well as its inactive mutant D119A (D→A point mutation at
position 119), were generously provided by Dr Mark H Gins-
berg (University of California at San Diego, San Diego, CA,
USA [34]). Retroviral β3 integrin vectors were synthesized by
PCR amplification using oligonucleotides containing BglII
(amino terminus) and XhoI (carboxyl terminus) restriction sites,
and subsequently ligated into identical sites immediately
upstream of the IRES in the bicistronic retroviral vector
pMSCV-IRES-GFP (plasmid murine stem cell virus-internal
ribosomal entry site-green fluorescent protein) or pMSCV-
IRES-YFP (yellow fluorescent protein). [35] All β3 integrin
inserts were sequenced in their entirety on an Applied Biosys-
tems 377A DNA sequencing machine (Applied Biosystems,
Foster City, CA USA).
Full-length human c-Src cDNA was PCR amplified from
IMAGE clone 4871614 (Invitrogen, Carlsbad, CA, USA) using
oligonucleotides containing HindIII (amino terminus) and XbaI
(carboxyl terminus) restriction sites, respectively. The resulting
PCR product was ligated into corresponding sites in
pcDNA3.1/Myc-His B vector (Invitrogen) to carboxyl-termi-
nally tag c-Src with a Myc and (His)6-tag. Kinase dead
(Lys295Met) or constitutively active (Tyr530Phe) c-Src
mutants were generated by site-directed mutagenesis using
the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA, USA). Afterward, Myc-His tagged WT and mutant c-
Src cDNAs were amplified by PCR and ligated into EcoRI
(amino terminus) and BglII (carboxyl terminus) restriction sites
in pMSCV-IRES-GFP. All c-Src inserts sequenced in their
entirety on an Applied Biosystems 377A DNA sequencing
machine.
NMuMG cells were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum (FBS)
and 10 µg/ml insulin. MCF10A and MCF10CA1a cells were
cultured as previously described [9]. Stable expression of indi-
vidual β3 integrin subunits or c-Src derivatives in NMuMG and
MCF10A cells was accomplished by their overnight infection
with control (i.e. pMSCV-IRES-GFP or pMSCV-IRES-YFP),
WT or D119A β3 integrin, or mutant c-Src retroviral superna-
tants produced by EcoPac2 retroviral packaging cells (Clon-
tech, San Diego, CA, USA), as described previously [36].
Cells expressing GFP, YFP, or both fluorescent proteins were
isolated and collected 48 hours later on a MoFlo cell sorter
(Cytomation, Fort Collins, CO, USA), and subsequently were
expanded to yield stable polyclonal populations of control (i.e.
GFP or YFP), β3 integrin (i.e. WT or D119A), or mutant c-Src
(i.e. kinase-dead or constitutively active) expressing cells.
Expression of recombinant β3 integrins in individual NMuMG
cell lines was monitored by immunoblotting detergent solubi-
lized whole cell extracts with antibodies against the extracellu-
lar domain of β3 integrin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), whereas expression of mutant c-Src protein
kinases was detected by immunoblotting with either anti-Src
(1:1000 dilution; Santa Cruz Biotechnology) or anti-Myc
(1:1000 dilution; Covance, Princeton, New Jersey USA) anti-
bodies.
Fluorescence-activated cell sorting analysis
Control (GFP), WT, or D119A β3 integrin expressing NMuMG
cells were cultured in the absence or presence of TGF-β1 (5
ng/ml) for 36 hours to stimulate EMT. Afterward, 1 × 106 cells
were trypsinized, washed, and incubated in fluorescence-acti-
vated cell sorter (FACS) buffer (1% bovine serum albumen in
phosphate-buffered saline [PBS]) supplemented with a 1:20
dilution of either PE-conjugated anti-mouse αv integrin (BD
Pharmingen, San Diego, CA, USA) or PE-conjugated anti-
human β3 integrin antibodies (BD Pharmingen). After a 30 min
incubation on ice, the cells were washed twice in PBS and
immediately fixed with 1% paraformaldehyde before fluores-
cence-activated cell sorting (FACS) analysis of αv  or  β3
expression in GFP-positive NMuMG cells.
Immunofluorescence studies
The ability of TGF-β to alter actin cytoskeletal architecture was
monitored essentially as described previously [37,38]. Briefly,
control or β3 integrin expressing NMuMG cells (30,000 cells/
well) were plated onto gelatin coated (0.1% in PBS) glass
coverslips in 24-well plates. The cells were stimulated with
TGF-β1 (5 ng/ml) for 0–36 hours at 37°C. In some experi-
ments, control or β3 integrin-expressing NMuMG cells were
stimulated with TGF-β1 in the absence or presence of the Src
kinase inhibitor PP2 (10 µmol/l; Calbiochem, Temecula, CA,
USA) or its inactive counterpart PP3 (10 µmol/l; Calbiochem).
Upon completion of agonist stimulation, the cells were washed
in PBS, fixed in 4% paraformaldehyde, and permeabilized by
Triton X-100 (0.2% in PBS). The cells were then blocked in
PBS supplemented with 1.5% FBS, followed by incubation
with TRITC-phalloidin or FITC-phalloidin (0.25 µmol/l). For
αvβ3 integrin staining, the cells were blocked in goat β-globulin
(200 µg/ml; Jackson Immunoresearch, West Grove, PA, USA)
before sequential incubations with anti-αvβ3 LM609 antibody
(1:250 dilution; BD Biosciences, San Jose, CA USA), fol-
lowed by biotinylated goat anti-mouse antibody (5 µg/ml; Jack-
son Immunoresearch) and finally by Alexa-streptavidin (1.2 µg/
ml; Invitrogen). All images were captured on a Nikon Diaphot
microscope.
RNA interference studies
NMuMG cells lacking either β3 integrin or c-Src were gener-
ated using SMARTpool small interfering RNAs (siRNAs), in
accordance with the manufacturer's recommendations (Dhar-
macon, Lafayette, CO, USA). Briefly, NMuMG cells (30,000
cells/well) were plated either onto plastic or gelatin coated
(0.1% in PBS) glass coverslips in 24-well plates and cultured
overnight in antibiotic-free media. Fresh media was added the
following morning and the cells were transiently transfectedBreast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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with DharmaFECT One reagent (Dharmacon) supplemented
with β3 integrin or c-Src siRNAs (100 nmol/l). Thirty-six hours
after transfection, the cells were treated with TGF-β1 (5 ng/ml)
for varying times at 37°C. Upon completion of agonist stimula-
tion, the cells were harvested and prepared for immunoblotting
and immunofluorescence analyses as above. NMuMG cell
transfection efficiency was monitored by co-transfection with
siGLO RISC-Free siRNA (Dharmacon), which was visualized
under fluorescent microscope.
Cellular phosphorylation assays
Control or β3 integrin-expressing NMuMG cells were cultured
onto 24-well plates (30,000 cells/well) and allowed to adhere
overnight. The next morning, the cells were washed twice in
PBS and placed in Dulbecco's modified Eagle's medium sup-
plemented with 0.5% FBS for 4 hours before stimulation with
TGF-β1 (5 ng/ml) for 0–120 min. In some experiments, the
cells were stimulated with Prolactin (100 ng/ml; generously
provided by National Hormone and Peptide Program, US
National Institutes of Health), 4α-phorbol 12-myristate 13-ace-
tate (PMA; 10 ng/ml; Sigma, St. Louis, MO, USA), or epider-
mal growth factor (EGF; 100 ng/ml; Upstate, Charlottesville,
VA). Afterward, the cells were washed in ice-cold PBS and
lysed in 200 µl of buffer H/1% Triton X-100 [36]. Detergent
solubilized whole cell extracts were prepared, clarified by
microcentrifugation, and subsequently concentrated by ace-
tone precipitation. Recovered proteins were fractionated
through 10% SDS-PAGE gels, immobilized electrophoreti-
cally to nitrocellulose membranes, and subsequently probed
with a 1:250 dilution of either anti-phospho-Smad2, -ERK1/2,
or -p38 MAPK polyclonal antibodies (Cell Signaling Technol-
ogy, Beverly, MA, USA). The resulting immunocomplexes were
visualized by enhanced chemiluminescence. Differences in
protein loading could not be readily monitored by b-actin
immunoreactivity because stable β3 integrin expression and
TGF-β stimulation significantly elevated b-actin expression in
MECs (data not shown [5,32,39]). Thus, differences in protein
loading were instead monitored by reprobing stripped mem-
branes with anti-ERK1/2 antibodies (1:2500 dilution; Upstate,
Charlottesville, VA USA), whose expression in MECs was
unaltered by TGF-β treatment [5,32,39].
Cell biological assays
The effect of WT and D119A β3 integrin expression on various
TGF-β stimulated activities in MECs was determined as fol-
lows: cell proliferation using 10,000 cells/well in a [3H]thymi-
dine incorporation assay, as described elsewhere [35]; cell
invasion induced by 10% serum using 350,000 cells/well in a
modified Boyden-chamber coated with Matrigel matrices
(diluted 1:25 in serum-free Dulbecco's modified Eagle's
medium), as described elsewhere [35,40]; and gene expres-
sion using 30,000 cells/well in a synthetic pSBE-luciferase
reporter gene assay, as described previously [35].
Iodinated transforming growth factor-β1 radioligand 
binding and cross-linking assay
Control and β3 integrin-expressing NMuMG cells were plated
onto 10 cm plates and grown until they reached 90% conflu-
ency. The radioligand binding and cross-linking of [125I]TGF-β1
(200 pmol/l) to NMuMG cells was performed as described
previously [41]. Afterward, cytokine:receptor complexes con-
tained in detergent-solubilized whole cell extracts were iso-
lated by immunoprecipitation with anti-TβR-II antibodies, as
described elsewhere [41]. Immunocomplexes were subse-
quently fractionated through 7.5% SDS-PAGE and then
immobilized electrophoretically to nitrocellulose and probed
with anti-β3 integrin antibodies. Iodinated TGF-β1 bound to cell
surface TβR-I and TβR-II was visualized by exposure of the
dried nitrocellulose membranes to a phosphor screen, which
was developed 1–3 days later on a Molecular Dynamics
Typhoon Scanner (GE Healthcare Bio-Sciences Corp., Pis-
cataway, NJ USA).
Integrin:TβR-II co-immunoprecipitation assays
Control (2.5 × 106) or β3  integrin (7 × 105) expressing
NMuMG cells were cultured onto 10 cm plates and subse-
quently stimulated with TGF-β1 (5 ng/ml) for varying times in
the absence or presence of the Src inhibitor PP2 (10 µmol/l).
In some cases, NMuMG cells were held in suspension and
replated onto culture dishes previously coated with vitronectin
(1 ng/ml; Chemicon, Temecula, CA, USA). Following agonist
stimulation, the cells were washed twice in ice-cold PBS and
disrupted in Nonidet P-40 lysis buffer [42] (Nonidet P-40;
Sigma). The resulting detergent-solubilized whole cell extracts
were clarified by microcentrifugation and subjected to the fol-
lowing immunoprecipitation conditions: anti-β1 integrin anti-
bodies (Santa Cruz Biotechnology) using 1 mg whole cell
extract; anti-β3  integrin antibodies using 1 mg whole cell
extract; anti-phosphotyrosine 4G10 antibodies (Upstate)
using 1 mg whole cell extract; or anti-TβR-I or -TβR-II antibod-
ies using 2 mg whole cell extract as described previously [43].
All immunoprecipitations were incubated for 16 hours at 4°C
with slow rotation. The resulting immunocomplexes were col-
lected by microcentrifugation, washed, fractionated through
10% SDS-PAGE gels, and transferred electrophoretically to
nitrocellulose membranes, which subsequently were probed
with anti-β3 integrin (1:1000), anti-TβR-II (1:1500; Santa Cruz
Biotechnology), or anti-phosphotyrosine 4G10 (1:1500;
Upstate) antibodies.
In vitro tyrosine kinase phosphorylation assays
Tyrosine phosphorylation of TβR-II was determined using an in
vitro protein kinase assay that measured the ability of either
active FAK or Src to phosphorylate recombinant glutathione
S-transferase (GST)-TβR-II, which contained only the cyto-
plasmic domain (i.e. the carboxyl terminal 380 amino acids) of
TβR-II fused to GST. Protein kinase reactions were performed
in a final volume of 30 µl, consisting of 1 µg of GST-TβR-II with
either 0.2 µg of FAK or 1 Unit of Src (Cell Signaling Technol-Available online http://breast-cancer-research.com/content/8/4/R42
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ogy). Reactions were initiated by addition of 10 µl of 4× assay
buffer [44] and were incubated for 30 min at 30°C. Afterward,
the reactions were stopped by addition of 4× sample buffer
[44] and boiled for 5 min. Reactions were diluted by addition
of 1 ml buffer H/Triton X-100 and immunoprecipitated over-
night with anti-TβR-II antibodies. The resulting immunocom-
plexes were collected, washed, and resuspended in 1X
sample buffer. GST fusion proteins were fractionated through
10% SDS-PAGE before their immobilization to nitrocellulose
membranes. Tyrosine phosphorylation of GST-TβR-II was vis-
ualized by immunoblotting nitrocellulose membranes with anti-
phosphotyrosine antibodies. Differences in immunoprecipita-
tion efficiency and loading were monitored by reprobing
stripped membranes with anti-TβR-II antibodies.
Recombinant GST-Smad3 phosphorylation assay
The phosphorylation of recombinant Smad3 by activated TβR
complexes was performed essentially as described previously
[45]. Briefly, quiescent NMuMG cells were pretreated with 10
µmol/l of either PP2 or SU6656 (EMD Biosciences, La Jolla,
CA, USA) for 1 hour at 37°C, and subsequently were stimu-
lated with TGF-β1 (5 ng/ml) for 30 min at 37°C. Cytokine stim-
ulations were terminated by washing the cells twice in ice-cold
PBS, which then were lysed and solubilized on ice in buffer H/
1% Triton X-100. The resulting cell extracts (1 mg/tube) were
clarified by microcentrifugation, and subsequently were immu-
noprecipitated with anti-TβR-II antibodies for 2 hours at 4°C.
TβR immunocomplexes were recovered by brief centrifugation
and subsequently were washed twice in PBS. TβR phospho-
transferase activity against recombinant GST-Smad3 was
measured for 30 min at 30°C in a final reaction volume of 40
µl consisting of 30 µl of TGF-β receptor complexes, 5 mg
GST-Smad3, and 10 µl of 4X assay buffer [43]. Phospho-
transferase reactions were stopped by the addition of 4X sam-
ple buffer and were boiled for 5 min before their fractionation
through 10% SDS-PAGE. Fractionated proteins were immo-
bilized electrophoretically to nitrocellulose membranes, which
subsequently were probed with anti-phospho-Smad2/3 anti-
bodies to visualize phosphorylated GST-Smad3. Differences
in immunoprecipitation efficiency and loading were monitored
by reprobing stripped membranes with anti-TβR-II antibodies.
Results
TGF-β1 mediated EMT increases cell surface αvβ3 integrin 
expression and β3 integrin:TβR-II complex formation in 
NMuMG cells
Alterations in cell microenvironments and stromal compart-
ments play critical roles in regulating the progression of tumors
from indolent to aggressive states [46,47]. Differential integrin
expression [27] and dysregulated TGF-β signaling [48] both
contribute to the remodeling of cancer cell microenviron-
ments, particularly those of the breast. Because integrins reg-
ulate MEC response to TGF-β [32], we hypothesized that
differential integrin expression induced by TGF-β would con-
tribute to its regulation of MEC proliferation and EMT. To test
this hypothesis, we stimulated normal mouse mammary epithe-
lial (NMuMG) cells with TGF-β1 and monitored changes in
actin stress fiber formation by immunofluorescence. As we
have shown previously [38], resting NMuMG cells exhibited
typical cuboidal epithelial cell morphology characterized by
strong cortical acting staining (Figure 1a). When stimulated
with TGF-β1, these cells underwent EMT and exhibited signif-
Figure 1
TGF-β1 mediated EMT increases cell surface αvβ3 integrin expression in  NMuMG cells TGF-β1 mediated EMT increases cell surface αvβ3 integrin expression in 
NMuMG cells. NMuMG cells were incubated in the absence or pres-
ence of TGF-β1 (5 ng/ml) for 0–36 hours and assayed for EMT. (a) 
Alterations in actin cytoskeletal architecture were visualized by direct 
rhodamine-phalloidin immunofluorescence and αvβ3 integrin by indirect 
immunofluorescence using anti-αvβ3 integrin (LM609) antibodies. 
Shown are representative images from a single experiment that was 
repeated twice with identical results. (b) Detergent-solubilized whole 
cell extracts (50 µg/lane) were prepared to analyze expression of the αv 
and β3 integrin subunits by immunoblotting. Differences in protein load-
ing were monitored by reprobing striped blots with anti-ERK1/2 anti-
bodies because, unlike the increase in β-actin expression observed 
(data not shown) ERK1/2 expression was unaltered in NMuMG cells in 
response to TGF-β1 treatment. (c) β3 Integrin deficient NMuMG cells 
were generated by siRNA transfection. The effects of β3 integrin defi-
ciency on TGF-β mediated EMT was visualized by direct FITC-phalloi-
din immunofluorescence. Shown are representative images from a 
single experiment that was repeated twice with identical results. Deter-
gent-solubilized whole cell extracts (50 µg/lane) were prepared to ana-
lyze expression of the αv, β3, and β1 integrin subunits by 
immunoblotting. Differences in protein loading were monitored by rep-
robing striped blots with anti-β-actin antibodies. EMT, epithelial-mesen-
chymal transitions; ERK, extracellular signal-regulated kinase; siRNA, 
small interfering RNA; TGF, transforming growth factor.Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
Page 6 of 16
(page number not for citation purposes)
icant formation of actin stress fibers that emanated from focal
adhesions (Figure 1a).
Because αvβ3 integrin expression is elevated in breast cancers
and enhances cancer cell invasion [27,30,31], we monitored
the ability of TGF-β to alter αvβ3 integrin expression in NMuMG
cells. Immunofluorescence analysis showed that TGF-β1 treat-
ment of NMuMG cells significantly induced their cell surface
expression of the αvβ3 integrin (Figure 1a). Western blot anal-
ysis confirmed the upregulation of αvβ3 integrin expression
upon TGF-β1 mediated EMT (Figure 1b). The association of
upregulated αvβ3 integrin expression with TGF-β stimulation of
EMT suggested that αvβ3 integrins may play an essential role
in facilitating EMT stimulated by TGF-β. We tested this hypoth-
esis by transiently transfecting NMuMG cells with siRNAs
directed against β3 integrin and subsequently monitored their
ability to undergo EMT in response to TGF-β. Figure 1c shows
that β3 integrin deficiency abolished the ability of TGF-β to
stimulate EMT in NMuMG cells. More importantly, NMuMG
cells transfected with β3 integrin siRNAs only exhibited rudi-
mentary EMT characteristics coordinate with the expression of
αvβ3 integrins, which exhibit significantly delayed expression in
response to TGF-β (Figure 1c). Moreover, β3 integrin defi-
ciency failed to alter NMuMG cell expression of β1 integrins
(Figure 1c), indicating that signals arising from β1 integrin were
insufficient in mediating EMT by TGF-β.
Collectively, these findings show that TGF-β induces EMT in
NMuMG cells, and that upregulated expression of αvβ3
integrin is essential for this process to occur. The findings also
Figure 2
TGF-β1 mediated EMT induces β3 integrin:TβR-II complex formation on  the cell surface of NMuMG cells TGF-β1 mediated EMT induces β3 integrin:TβR-II complex formation on 
the cell surface of NMuMG cells. NMuMG cells were incubated in the 
absence or presence of TGF-β1 (5 ng/ml) for 0–30 hours to induce 
EMT. Detergent-solubilized whole cell extracts (1 mg/tube) were immu-
noprecipitated with (a,b) anti-β3 or (b) anti-β1 integrin antibodies, and 
subsequently immunoblotted with anti-TβR-II antibodies. Shown are 
representative immunoblots from a single experiment that was repeated 
twice with identical results. EMT, epithelial-mesenchymal transitions; 
TβR; TGF receptor; TGF, transforming growth factor; WCE, whole cell 
extracts.
Figure 3
β3 Integrin overexpression in NMuMG cells β3 Integrin overexpression in NMuMG cells. NMuMG cells were engi-
neered by bi-cistronic retroviral transduction to stably express GFP 
alone (control), WT β3 integrin (WT) and GFP, or its inactive mutant 
D119A and GFP. (a) Detergent-solubilized whole cell extracts (50 µg/
lane) were prepared to analyze expression of the αv and β3 integrin sub-
units, and of TβR-II. Differences in protein loading were monitored by 
immunoblotting ERK1/2, whose expression in NMuMG cells was not 
altered by TGF-β treatment. (b) The percentage of NMuMG cells 
expressing human recombinant β3 integrin or endogenous αv integrin 
was determined by FACS analysis of cells incubated with either anti-
human β3 integrin or anti-mouse αv integrin antibodies. Histograms 
depict β3 and αv expression only in GFP-positive NMuMG cells and are 
from a representative experiment that was repeated twice with similar 
results. (c) Iodinated TGF-β1 was bound and chemically cross-linked to 
control (GFP), WT, and D119A β3 integrin expressing cells. 
Cytokine:receptor complexes were isolated by immunoprecipitation 
with anti-TβR-II antibodies, fractionated through 7.5% SDS-PAGE gels, 
and immobilized electrophoretically to nitrocellulose membranes. The 
upper panel shows a representative phosphor image of iodinated TGF-
β1 bound to TβR-I and TβR-II. The middle panel shows that β3 integrin 
was present in isolated iodinated TGF-β1:receptor complexes as 
detected by anti-β3 integrin Western blot analysis of anti-TβR-II immu-
nocomplexes. Differences in protein loading were monitored by probing 
detergent-solubilized whole cell extracts (50 µg/lane) with anti-ERK1/2 
antibodies (bottom panel). BXL, binding and cross-linking; ERK, extra-
cellular signal-regulated kinase; GFP, green fluorescent protein; WT, 
wild type; TβR, TGF receptor; TGF, transforming growth factor; WCE, 
whole cell extracts.Available online http://breast-cancer-research.com/content/8/4/R42
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raise the possibility that β3 integrins may play a direct role in
regulating various MEC responses to TGF-β3.
Integrins regulate growth factor signaling in part via formation
of integrin:RTK complexes [23,24]. Based on our findings pre-
sented in Figure 1, we hypothesized that β3 integrins interact
physically with cell surface TβRs. In testing this hypothesis,
NMuMG cells were stimulated with TGF-β for various periods
of time, whereupon whole cell extracts were prepared and
immunoprecipitated with anti-β3 integrin antibodies. Probing
the resulting immunocomplexes with anti-TβR-II antibodies
showed that β3 integrin did indeed interact with TβR-II (Figure
2a), and that EMT was necessary to induce this event. In addi-
tion, detergent-solubilized whole cell extracts prepared from
control and TGF-β stimulated NMuMG cells were immunopre-
cipitated with antibodies against either β1 or β3 integrins, and
the resulting immunocomplexes were probed for TβR-II. Figure
2b shows that β1 integrins interacted constitutively with TβR-
II, whereas EMT was again required to promote the associa-
tion of β3 integrin with TβR-II. Collectively, these findings indi-
cate that the formation of β3 integrin:TβR-II complexes is an
EMT-specific phenomena that may play an important role in
regulating TGF-β stimulation of EMT in NMuMG cells.
β3 Integrin overexpression in NMuMG cells
To further explore the role of β3 integrin in regulating MEC
function and TGF-β biology, we used bi-cistronic retroviral
transduction to stably express β3 integrin or its inactive coun-
terpart D119A-β3 integrin [34] in NMuMG cells. The D119A-
β3 integrin contains a point mutation in the conserved RGD
integrin binding motif and therefore fails to bind RGD-contain-
ing ligands, such as fibronectin, vitronectin, and osteopontin
[49,50]. Recombinant β3 integrin expression in NMuMG cells
was confirmed by immunoblotting whole cell extracts from
basal or TGF-β1 treated cells (Figure 3a). As observed previ-
ously, TGF-β stimulation of EMT in NMuMG cells induced their
expression of αv integrin (Figures 1 and 3a). Interestingly, WT
β3  integrin expression induced a dramatic compensatory
upregulation of αv integrin expression in NMuMG cells (Figure
3a). This β3 integrin response, which was independent of TGF-
β administration, was mimicked moderately by expression of
its inactive D119A counterpart (Figure 3a). Although D119A
β3 integrin is considered to be functionally inactive, its heterol-
ogous expression in cells can elicit partial biologic activity in
part through its ability to bind non-RGD-containing ligands,
such as plasminogen [51]. Thus, these findings suggest that
signals arising from activated β3 integrins induce αv integrin
expression in MECs.
To confirm that recombinant β3 integrins were expressed on
the cell surface of NMuMG cells, control or TGF-β1 treated
cells were incubated with PE-conjugated anti-human β3
integrin antibodies, and subsequently analyzed by FACS anal-
ysis. As expected, retrovirally infected NMuMG cells
expressed WT and D119A β3 integrins on their cell surfaces
(Fig. 3b, left). In addition, β3 integrin expressing cells were also
incubated with PE-conjugated anti-mouse αv integrin antibod-
ies, which confirmed the compensatory upregulation of αv
integrins and showed their ability to form functional complexes
with cell surface β3 integrin (Figure 3b, right).
Finally, iodinated TGF-β1 radioligand binding and cross-linking
assays were performed to confirm that β3 integrins did indeed
interact with TβR-II at the cell surface. As shown in Figure 3c,
WT and D119A β3 integrins both interacted with TβR-II at the
cell surface, indicating that formation of this complex is inde-
pendent of β3 integrin activation. Quite surprisingly, WT β3
integrin expression, but not that of D119A, increased cell sur-
face expression of TβR-II (Figure 3c). Indeed, the ratio of TβR-
II:TβR-I detected at the cell surface in WT β3 integrin express-
ing NMuMG cells (1.31 ± 0.14; n = 4) was significantly higher
(P = 0.009, Student's t-test) than those observed in their GFP
β3 integrin (0.76 ± 0.05; n = 4) and D119A β3 integrin (0.72
± 0.31; n = 4) expressing counterparts. Interestingly, semi-
quantitative real-time PCR analyses failed to detect differ-
ences in TβR-II transcript expression between these individual
NMuMG cell lines (data not shown), suggesting that signals
arising from β3 integrins alter TβR-II translocation to and/or
internalization from the cell surface of MECs.
Collectively, these findings show that retrovirally expressed
human β3 integrins were translocated to the cell surface of
NMuMG cells, where they formed active heterodimers with αv
integrin, and more importantly they interacted physically with
TβR-II at the plasma membrane. In addition, these findings and
those presented in Figures 1 and 2 illustrate a unique and
essential role for β3 integrin in promoting EMT, particularly that
mediated by TGF-β, and suggest that the formation of β3
integrin:TβR-II complexes may alter the response of MECs to
TGF-β by regulating its intracellular signaling systems.
β3 Integrin expression enhances MAPK activation by 
TGF-β in NMuMG cells
The coupling of integrins to RTKs often is associated with acti-
vation of MAPKs [23,52]. This is noteworthy because the acti-
vation of MAPKs is essential for the ability of TGF-β to promote
EMT [2,15,16]. We therefore determined whether β3 integrin
expression altered the ability of TGF-β to activate MAPKs in
NMuMG cells. Although expression of β3 integrin in NMuMG
cells had negligible effects on TGF-β stimulated Smad2 phos-
phorylation (Figure 4a) and nuclear translocation (data not
shown), its expression significantly enhanced the activation of
ERK1/2 and p38 MAPK by TGF-β (Figure 4a). Integrin expres-
sion can elicit dramatic changes in cell adhesion and morphol-
ogy [23], potentially resulting in global alterations in
intracellular signaling systems. To determine the specificity of
β3 integrin expression to TGF-β signaling, we monitored the
activation status of p38 MAPK in control and β3  integrin
expressing NMuMG cells before and after their stimulation
with TGF-β1, prolactin, PMA, or EGF. Figure 4b shows that β3Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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integrin expression selectively regulated the coupling of TGF-
β, but not that of prolactin, PMA, or EGF, to p38 MAPK activa-
tion in NMuMG cells. Thus, these findings implicate β3
integrins as unique mediators of TGF-β signaling in MECs.
β3 Integrin expression blocked TGF-β stimulated growth 
arrest but enhanced TGF-β mediated invasion and EMT 
in NMuMG cells
Based upon the ability of β3 integrins to enhance MAPK acti-
vation by TGF-β, we next sought to determine whether β3
integrins could alter the ability of TGF-β to regulate MEC cell
proliferation, invasion, and EMT. We first measured the effects
of β3 integrin expression on the rate of DNA synthesis in rest-
ing NMuMG cells. As compared with GFP expressing
NMuMG cells, those expressing WT β3 integrin exhibited sig-
nificantly increased rates of DNA synthesis (by 78 ± 0.12%; n
= 3; P = 0.002), whereas those expressing D119A β3 integrin
exhibited significantly retarded rates of DNA synthesis (by 68
± 4.0%; n = 3; P = 0.00007). Despite the relative growth rate
differences observed between these β3 integrin expressing
NMuMG cell derivatives, the response of GFP and D119A
expressing NMuMG cells to TGF-β mediated cytostasis was
surprisingly similar (Figure 5a). In contrast, WT β3 integrin
expression significantly reduced the ability of TGF-β to induce
growth arrest in NMuMG cells (Figure 5a), indicating that β3
integrin expression significantly reduces cytostasis mediated
by TGF-β, thereby circumventing its tumor suppressor func-
tion in MECs.
Figure 4
β3 Integrin enhances MAPK activation by TGF-β in NMuMG cells β3 Integrin enhances MAPK activation by TGF-β in NMuMG cells. (a) 
Control or β3 integrin expressing NMuMG cells were serum starved for 
4 hours prior to TGF-β1 stimulation (5 ng/ml) for 0–120 min. Afterward, 
the activation status of Smad2, ERK1/2, and p38 MAPK was deter-
mined by immunoblot analysis using phospho-specific antibodies. Rep-
robing stripped membranes with anti-ERK1/2 antibodies monitored 
differences in protein loading. (b) Control or β3 integrin-expressing 
NMuMG cells were serum starved for 4 hours before stimulation with 
TGF-β1 (5 ng/ml), prolactin (100 ng/ml), PMA (10 ng/ml), or EGF (100 
ng/ml) for 30 min. Afterward, the activation status of p38 MAPK was 
determined by immunoblot analysis using phospho-specific antibodies. 
Reprobing stripped membranes with anti-pan p38 MAPK antibodies 
was used to monitor differences in protein loading. Accompanying 
graphs depict the mean (± standard error) fold increase of p38 MAPK 
stimulation observed in three independent experiments (*P < 0.05). 
EGF, epidermal growth factor; ERK, extracellular signal-regulated 
kinase; MAPK, mitogen-activated protein kinase; PMA, 4α-phorbol 12-
myristate 13-acetate; TGF, transforming growth factor.
Figure 5
β3 Integrin expression blocks TGF-β stimulated growth arrest but  enhances TGF-β stimulated invasion and EMT in NMuMG cells β3 Integrin expression blocks TGF-β stimulated growth arrest but 
enhances TGF-β stimulated invasion and EMT in NMuMG cells. (a) 
Control (GFP), WT, or D119A β3 integrin expressing NMuMG cells 
were stimulated with increasing concentrations of TGF-β1 for 48 hours. 
Cellular DNA was radiolabeled with [3H]thymidine and quantified by 
scintillation counting. Data are the means (± standard error) of three 
independent experiments presented as the percentage of [3H]thymi-
dine incorporation normalized to untreated cells. (b) Control (GFP) and 
β3 integrin expressing NMuMG cells were allowed to invade through 
Matrigel matrices in the absence or presence of TGF-β1 (5 ng/ml) for 
36 hours. Values are the mean (± standard error) of three independent 
experiments presented as the percentage invasion relative to TGF-β 
stimulated β3 integrin expressing NMuMG cells. (c) The cell morphol-
ogy of control (GFP), WT, and D119A β3 integrin expressing NMuMG 
cells was monitored by phase contrast microscopy, and alterations in 
actin cytoskeletal architecture was visualized by direct rhodamine-phal-
loidin immunofluorescence. Shown are representative images from a 
single experiment that was repeated twice with identical results. (d) 
Control (GFP), WT, or D119A β3 integrin expressing NMuMG cells 
were transiently transfected with pSBE-luciferase and pCMV-β-gal 
cDNAs, and subsequently were stimulated with TGF-β1 (5 ng/ml) for 
24 hours. Afterward, luciferase and β-gal activities contained in deter-
gent-solubilized cell extracts were measured. Values are the mean (± 
standard error) luciferase activities observed in three independent 
experiments normalized to maximal reporter gene expression measured 
in unstimulated cells. EMT, epithelial-mesenchymal transitions; GFP, 
green fluorescent protein; TGF, transforming growth factor; WT, wild 
type; SBE, Smad binding element.Available online http://breast-cancer-research.com/content/8/4/R42
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We also determined whether β3  integrins are capable of
enhancing the tumor promoting functions of TGF-β. In doing
so, we compared the ability of β3 integrin expressing NMuMG
cell lines to invade through synthetic basement membranes.
As shown in Figure 5b, GFP expressing NMuMG cells exhib-
ited minimal invasion through Matrigel matrices in response to
serum stimulation, a response that was enhanced insignifi-
cantly by TGF-β treatment. Similar to its inability to alter growth
regulation by TGF-β, expression of the D119A β3 integrin in
NMuMG cells failed to affect their TGF-β regulated invasive-
ness (Figure 5b). In contrast, NMuMG cells expressing β3
integrin exhibited a trend toward increased invasiveness to
serum as compared with control cells (Figure 5b); however,
when stimulated with TGF-β1 these cells exhibited significantly
enhanced invasion through synthetic basement membranes
(Figure 5b). Because increased invasiveness is often associ-
ated with EMT [11], we examined the morphology and actin
cytoskeleton of NMuMG cells expressing β3 integrins. Con-
sistent with our previous results, only those NMuMG cells that
expressed WT β3 integrin acquired an elongated, fibroblast-
like morphology (Figure 5c), complete with the formation of
actin stress fibers (Figure 5c). Taken together, these findings
suggest that although both WT and D119A β3 integrins can
form complexes with TβR-II at the cell surface, only functional
β3 integrins are capable of inducing EMT and invasion in
NMuMG cells.
Lastly, we monitored changes in TGF-β stimulated gene
expression by measuring differences in luciferase expression
driven by the synthetic SBE (Smad binding element) promoter.
Figure 5d shows that only WT β3 integrin expression signifi-
cantly enhanced TGF-β stimulated gene expression as com-
pared with control cells or those expressing its inactive β3
integrin counterpart.
Collectively, these findings indicate that, unlike its nonfunc-
tional counterparts, expression of WT β3 integrin in MECs
diminished TGF-β mediated growth arrest, enhanced TGF-β
mediated invasion and EMT, and augmented TGF-β mediated
gene expression. Moreover, our results suggest that β3
integrin expression translates TGF-β from an inhibitor of MEC
cell growth to a stimulator of their invasion and EMT.
Dual receptor activation induces Src-mediated TβR-II 
tyrosine phosphorylation
Our findings thus far show that β3 integrin and TβR-II interact
upon TGF-β stimulation, β3 integrin expression is essential for
EMT stimulated by TGF-β, and β3 integrin expression influ-
ences the MEC response to TGF-β. To further explore the con-
sequences of β3  integrin:TβR-II complex formation, GFP
expressing NMuMG cells were incubated in the absence or
presence of TGF-β for 36 hours, and subsequently were held
in suspension before re-plating onto plastic or vitronectin-
coated wells in the absence or presence of TGF-β1 for 5 min.
Afterward, the phosphorylation status of TβR-II and its ability
Figure 6
Dual receptor activation induces Src mediated TβR-II tyrosine phos- phorylation Dual receptor activation induces Src mediated TβR-II tyrosine phos-
phorylation. (a) GFP-expressing NMuMG cells were stimulated with 
TGF-β1 (5 ng/ml) for 36 hours to induce β3 integrin expression and 
EMT. Afterward, the cells were dissociated and re-plated either onto 
plastic or vitronectin-coated wells in the absence or presence of TGF-
β1 (5 ng/ml) for 5 min. Afterward, detergent-solubilized whole cell 
extracts were prepared (1 mg/tube) and subsequently immunoprecipi-
tated with anti-phosphotyrosine or anti-β3 integrin antibodies as indi-
cated. The presence of TβR-II in precipitated immunocomplexes was 
determined by Western blotting with anti-TβR-II antibodies. Differences 
in protein loading were monitored by immunoblotting whole cell 
extracts (50 mg/lane) for β3 integrin and TβR-II. Shown are representa-
tive immunoblots from a single experiment that was repeated twice with 
similar results. (b) Resting WT β3 integrin-expressing NMuMG cells 
were dissociated and re-plated as above. Afterward, TβR-II tyrosine 
phosphorylation and complex formation with β3 integrin was determined 
by immunoblotting as above. Shown are representative immunoblots 
from a single experiment that was repeated three times with identical 
results. (c) Active recombinant Src (1 unit/reaction) or FAK (0.2 µg/
reaction) kinases were added to protein kinase reaction mixtures con-
taining 1 µg/tube of either kinase active (WT) or inactive (K277R) GST-
TβR-II. Phosphorylation reactions were stopped after 30 min and the 
phosphorylation status of TβR-II was determined by immunoprecipita-
tion of diluted protein kinase reaction mixtures with anti-TβR-II antibod-
ies. Afterward, immobilized immunocomplexes were probed 
sequentially with anti-phosphotyrosine antibodies, followed by anti-
TβR-II antibodies as indicated (*autophosphorylated recombinant Src; 
**autophosphorylated recombinant FAK). Data are from a representa-
tive experiment that was repeated three times with similar results. (d) 
Recombinant Src and FAK were incubated in protein kinase assay 
buffer for 30 min at 30°C. The data show the autophosphorylation on 
tyrosine residues of recombinant Src (*) and FAK (**) as determined by 
immunoblotting with anti-phosphotyrosine antibodies. Data are from a 
representative experiment that was repeated at least three times with 
similar results. EMT, epithelial-mesenchymal transitions; FAK, focal 
adhesion kinase; GST, glutathione S-transferase; TβR, TGF-β receptor; 
TGF, transforming growth factor; WCE, whole cell extracts; WT, wild 
type.Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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to form complexes with β3 integrin were monitored by co-
immunoprecipitation analyses. Figure 6a shows that following
TGF-β induced EMT, TβR-II was constitutively tyrosine phos-
phorylated and associated with β3 integrin. Because chronic
TGF-β stimulation of NMuMG cells induces β3 integrin expres-
sion (Figure 1) and complex formation with TβR-II (Figure 2), it
was difficult to assess the role of TGF-β receptor and integrin
stimulation in the formation of β3 integrin:TβR-II complexes in
NMuMG cells. To circumvent this difficulty, resting WT β3
integrin expressing NMuMG cells were dissociated and sub-
sequently replated and stimulated for 5 min, as above. Figure
6b shows that TβR-II only interacted with β3 integrins upon
TGF-β1 stimulation and, more importantly, that this response
was enhanced significantly upon β3 integrin adhesion. In addi-
tion, only upon dual receptor activation (i.e. β3 integrin and
TβRs) was TβR-II phosphorylated on tyrosine residues (Figure
6b). Thus, β3 integrin regulates TGF-β signaling by targeting
TβR-II for tyrosine phosphorylation in a manner reminiscent of
integrin actions on RTK signaling [23].
Although integrins lack intrinsic protein tyrosine kinase (PTK)
activity, they facilitate tyrosine phosphorylation of target pro-
teins via their recruitment of FAK and Src PTKs to focal adhe-
sions [22]. We therefore hypothesized that FAK or Src are
potential PTKs responsible for phosphorylating TβR-II on tyro-
sine residues in NMuMG cells. We tested this hypothesis by
utilizing an in vitro PTK assay that measured the ability of puri-
fied, active FAK or Src to phosphorylate GST fusion proteins
containing catalytically active or inactive (i.e. K277R) versions
of the cytoplasmic domain of TβR-II. As shown in Figure 6c,
Src phosphorylated the cytoplasmic domain of TβR-II on tyro-
sine residues. Although active and capable of undergoing
autophosphorylation on tyrosine residues (Figure 6d), FAK
was unable to phosphorylate TβR-II in vitro (Figure 6c), sug-
gesting that Src phosphorylates TβR-II in response to β3
integrin expression.
To further examine the functional link between Src and TβR-II,
we attempted to inhibit Src activity or function in NMuMG cells
and subsequently monitor the consequences of these manip-
ulations on TβR-II tyrosine phosphorylation. Recent work con-
ducted by Maeda and coworkers [53] showed that the broad
spectrum protein kinase inhibitor PP1 antagonizes TGF-β sig-
naling by inhibiting TβR-I and TβR-II protein kinase activity. As
such, we monitored the effects of two Src inhibitors, PP2 and
SU6656, on the ability of immunoprecipitated TGF-β receptor
complexes to phosphorylate recombinant GST-Smad3 in
vitro. As expected, TGF-β stimulation greatly enhanced the
phosphorylation of recombinant Smad3 (Figure 7a), a reaction
that was reduced markedly by SU6656 administration (Figure
7a). In contrast, PP2 treatment failed to inhibit TβR activity and
instead appeared to elicit agonist independent receptor acti-
vation (Figure 7a). Based on its inactivity against TβRs, PP2
appeared to be a suitable pharmacological agent to inhibit Src
activity in MECs. Accordingly, β3 integrin-expressing NMuMG
Figure 7
Src inhibition blocks TβR-II tyrosine phosphorylation in NMuMG cells Src inhibition blocks TβR-II tyrosine phosphorylation in NMuMG cells. 
(a) NMuMG cells were pretreated for 60 min with either PP2 (10 µmol/
l) or SU6656 (10 µmol/l). Afterward, the cells were stimulated with 
TGF-β1 (5 ng/ml) for 20 min, and subsequently were lysed and immu-
noprecipitated (1 mg/tube) with anti-TβR-II antibodies. The resulting 
immunocomplexes were used to phosphorylate recombinant GST-
Smad3, which was visualized by immunoblotting with anti-phospho-
Smad2 antibodies. Data are from a representative experiment that was 
repeated three times with similar results. (b) Control or β3 integrin 
expressing NMuMG cells were stimulated with TGF-β1 (5 ng/ml) in the 
absence or presence the Src inhibitor PP2 (10 µmol/l), as indicated. 
Afterward, detergent-solubilized whole cell extracts were prepared, 
immunoprecipitated, and subjected to Western blot analysis either with 
anti-phosphotyrosine (2 mg WCE/tube) or anti-TβR-II (1 mg WCE/
tube) antibodies as indicated. Differences in protein loading were mon-
itored by probing detergent-solubilized whole cell extracts (50 µg/lane) 
with anti-ERK1/2 antibodies (bottom panel). (c) WT β3 integrin 
expressing NMuMG cells were transiently transfected with cDNAs 
encoding either constitutively active (CA) or dominant negative (DN) 
Src. Afterward, detergent solubilized whole cell extracts were prepared, 
immunoprecipitated with anti-phosphotyrosine (1 mg WCE/tube), and 
subjected to WB analysis with anti-TβR-II antibodies. Total Src expres-
sion was monitored by probing detergent solubilized whole cell extracts 
(50 µg/lane) with anti-Src antibodies, whereas exogenous Src expres-
sion was confirmed by reprobing stripped membranes with anti-Myc 
antibodies. Differences in protein loading were monitored by probing 
stripped membranes with anti-TβR-II antibodies. ERK, extracellular sig-
nal-regulated kinase; GST, glutathione S-transferase; IP, immunopre-
cipitated; PY, phosphotyrosine; TβR, TGF-β receptor; TGF, 
transforming growth factor; WB, Western blot; WCE, whole cell 
extracts; WT, wild type.Available online http://breast-cancer-research.com/content/8/4/R42
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cells treated with PP2 abrogated the tyrosine phosphorylation
of TβR-II in TGF-β stimulated NMuMG cells (Figure 7b), indi-
cating that Src activity does indeed mediate tyrosine phospho-
rylation of TβR-II in β3 integrin expressing NMuMG cells. Along
these lines, transient expression of constitutively active Src in
β3 integrin expressing NMuMG cells resulted in significantly
elevated tyrosine phosphorylation of TβR-II, an event that was
not recapitulated by expression of dominant negative Src (Fig-
ure 7c). Taken together, these findings indicate that β3
integrin-mediated recruitment of Src facilitates the tyrosine
phosphorylation of TβR-II in MECs, and that this phosphoryla-
tion event may act to enhance their proliferation, invasion, and
EMT by augmenting the ability of TGF-β to activate MAPKs.
Src inhibition blocks β3 integrin and TGF-β mediated 
MAPK activation, EMT, and invasion in NMuMG cells
We next explored the functional importance of Src in regulat-
ing various MEC responses to TGF-β. To do so, NMuMG cells
were pretreated with either PP2 or its inactive counterpart
PP3 and subsequently stimulated with TGF-β to activate
ERK1/2 and p38 MAPK. As expected, β3 integrin expression
significantly increased ERK1/2 and p38 MAPK activation fol-
Figure 8
Src inhibition blocks β3 integrin and TGF-β mediated MAPK activation, EMT, and invasion in NMuMG cells Src inhibition blocks β3 integrin and TGF-β mediated MAPK activation, EMT, and invasion in NMuMG cells. (a) Control or β3 integrin expressing 
NMuMG cells were serum starved for 4 hours before TGF-β1 (5 ng/ml) stimulation in the absence or presence of either PP2 (10 µmol/l) or its inac-
tive counterpart PP3 (10 µmol/l). Afterward, the activation status of ERK1/2 and p38 MAPK was determined by immunoblot analysis using phospho-
specific antibodies. Re-probing stripped membranes with anti-ERK1/2 antibodies monitored differences in protein loading. Data are from a repre-
sentative experiment that was repeated twice with similar results. (b) β3 Integrin expressing NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 
36 hours in the absence or presence of PP2 (10 µmol/l). Afterward, alterations in actin cytoskeletal architecture were visualized by direct rhodamine-
phalloidin immunofluorescence. Shown are representative images from a single experiment that was repeated twice with identical results. (c) Con-
trol (GFP) or DN Src-expressing NMuMG cells were stimulated with TGF-β1 (5 ng/ml) for 24 hours. Afterward, alterations in actin cytoskeletal archi-
tecture were visualized by direct rhodamine-phalloidin immunofluorescence. Total Src expression was monitored by probing detergent-solubilized 
whole cell extracts (50 µg/lane) with anti-Src antibodies, whereas exogenous Src expression was visualized using anti-Myc antibodies. Immunoblot-
ting stripped membranes with anti-β-actin antibodies served to monitor differences in protein loading. Shown are representative images from a single 
experiment that was repeated twice with identical results. (d) Control (GFP), DN Src, CA Src, β3 integrin, and β3 integrin/DN Src expressing 
NMuMG cells were allowed to invade through Matrigel matrices in the absence or presence of TGF-β1 (5 ng/ml) for 36 hours. Values are the mean 
(± standard error) of three independent experiments presented as the number of cells invaded per well. (e) Src-deficient NMuMG cells were gener-
ated by siRNA transfection. The effects of Src deficiency on TGF-β mediated EMT were visualized by direct FITC-phalloidin immunofluorescence. 
Shown are representative images from a single experiment that was repeated twice with identical results. Detergent-solubilized whole cell extracts 
(50 µg/lane) were prepared to monitor Src expression by immunoblotting with anti-Src antibodies. Differences in protein loading were monitored by 
re-probing striped blots with anti-β-actin antibodies. CA, constitutively active; DN, dominant negative; ERK, extracellular signal-regulated kinase; 
GFP, green fluorescent protein; MAPK, mitogen-activated protein kinase; TGF, transforming growth factor; WB, Western blot; WT, wild type.Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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lowing TGF-β1 stimulation (Figure 8a). This response to TGF-
β was unaffected by PP3 administration, but it was reduced
significantly by PP2 treatment of NMuMG cells (Figure 8a).
More importantly, PP2 administration completely reverted the
EMT phenotype induced by expression of β3  integrin in
NMuMG cells, and nearly abolished the ability of TGF-β to
stimulate EMT in NMuMG cells (Figure 8b). We also engi-
neered NMuMG cells to stably express dominant negative Src
and subsequently measured its effect on the ability of TGF-β
to induce EMT and invasion in MECs. As expected, GFP
expressing NMuMG cells readily underwent EMT when stimu-
lated by TGF-β (Figure 8c). In stark contrast, NMuMG cells
expressing dominant negative Src were stunted in their ability
to undergo EMT in response to TGF-β (Figure 8c), and instead
formed small, disorganized stress fibers that contrasted
sharply with those produced in their GFP expressing counter-
parts.
Proper organization of cell polarity is essential for cancer cell
invasion and metastasis [54]. Based on the aberrant EMT
response observed in dominant negative Src expressing
NMuMG cells, we suspected that their invasion through syn-
thetic basement membranes would also be impaired. Accord-
ingly, dominant negative Src expression significantly inhibited
the ability of TGF-β to induce NMuMG cell invasion (Figure
8d). Interestingly, singular expression of either constitutively
active Src or β3  integrin in NMuMG cells significantly
enhanced tonic and TGF-β stimulated cell invasion (Figure
8d). More importantly, introducing dominant negative Src into
β3 integrin expressing NMuMG cells completely abolished the
ability of TGF-β to stimulate cell invasion in MECs (Figure 8d).
Thus, activity of both β3 integrin and Src is necessary for MEC
invasion stimulated by TGF-β.
Finally, the findings above suggest that Src may play an essen-
tial role in facilitating EMT stimulated by TGF-β. We tested this
hypothesis by transiently transfecting NMuMG cells with siR-
NAs directed against Src and subsequently monitored their
ability to undergo EMT in response to TGF-β. Figure 8e shows
that Src deficiency did indeed abolish the ability of TGF-β to
stimulate EMT in NMuMG cells, a response reminiscent of that
observed in NMuMG cells deficient in β3 integrin (Figure 1c).
Collectively, these findings indicate that Src expression and
activity are essential for the ability of TGF-β to stimulate
MAPKs, and to induce EMT and cell invasion in MECs.
β3 Integrin expression increases in malignant human 
MECs and regulates invasion stimulated by TGF-β
Our findings have thus far solely investigated the relationship
between β3 integrins and TGF-β in normal MECs. It should be
noted that cells undergoing neoplastic transformation, includ-
ing those of the breast [26,27], exhibit altered integrin expres-
sion profiles during tumorigenesis, suggesting that integrins
could play a key role in the acquisition of neoplastic pheno-
types. The human MCF10A system consists of a series MEC
cell lines that share a common ancestry and represent distinct
stages of breast cancer development, ranging from normal to
highly invasive and metastatic [55]; they also represent a
model system for studying the conversion of TGF-β from a
tumor suppressor to a tumor promoter [9].
Interestingly, breast cancer progression was associated with
elevated expression of β3 integrin and its effector, FAK, which
correlated with the conversion of TGF-β from a suppressor to
Figure 9
β3 Integrin expression increases in malignant human MECs and regu- lates invasion stimulated by TGF-β β3 Integrin expression increases in malignant human MECs and regu-
lates invasion stimulated by TGF-β. (a) Detergent-solubilized whole cell 
extracts (100 µg/lane) of MCF10A and MCF10CA1a cells were pre-
pared to analyze expression of the β3 integrin subunit and FAK by 
immunoblotting. Differences in protein loading were monitored by prob-
ing striped blots with anti-TβR-II antibodies. Control (GFP) and β3 
integrin expressing (b) MCF10A cells or (c) MCF10CA1a cells were 
allowed to invade through Matrigel matrices in the absence or pres-
ence of TGF-β1 (5 ng/ml) for 36 hours. Values are the mean (± stand-
ard error) of three independent experiments presented as the 
percentage invasion relative to TGF-β stimulated WT β3 integrin 
expressing cells. FAK, focal adhesion kinase; MEC, mammary epithelial 
cell; TβR, TGF-β receptor; TGF, transforming growth factor; WT, wild 
type.Available online http://breast-cancer-research.com/content/8/4/R42
Page 13 of 16
(page number not for citation purposes)
a promoter of breast cancer progression (Figure 9a). Moreo-
ver, exogenous β3 integrin expression in normal, poorly inva-
sive MCF10A cells significantly enhanced their invasion
through synthetic basement membranes in response to TGF-
β (Figure 9b). In contrast, the malignant, metastatic
MCF10CA1a cells readily invaded Matrigel matrices when
stimulated with TGF-β, a response that was augmented signif-
icantly by WT β3 integrin expression (Figure 9c). Importantly,
D119A β3 integrin expression completely abolished the ability
of TGF-β to stimulate MCF10ACA1a cell invasion (Figure 9c).
Collectively, our findings suggest that mammary tumorigene-
sis alters β3 integrin expression in neoplastic MECs, and that
β3 integrins may play a crucial role in translating TGF-β from a
suppressor to a promoter of breast cancer growth and inva-
sion.
Discussion
The process of EMT recently has been subject to intense
research investigation because of its importance in mediating
cancer cell motility, invasion, and metastasis [11,48]. TGF-β is
a major regulator of both developmental and pathological
EMT, particularly that in diseased MECs, which frequently
exhibit decreased cytostasis and increased invasiveness in
response to TGF-β [56]. Unfortunately, the molecular mecha-
nisms underlying the conversion of TGF-β from an inhibitor of
MEC proliferation to an inducer of their EMT are poorly under-
stood. Because cell microenvironmental changes regulate
cancer development and progression, including the acquisi-
tion of EMT, and because integrins and TGF-β are major reg-
ulators of cell microenvironments, we hypothesized that
differential integrin expression induced by TGF-β would con-
tribute to its regulation of MEC proliferation and EMT.
To this end, we now show that β3 integrin expression alters the
response of MECs to TGF-β, particularly its ability to regulate
cell proliferation, invasion, and EMT. Indeed, β3 integrin expres-
sion appears essential for TGF-β stimulation of EMT (Figure
1c). Moreover, we demonstrate that β3 integrin directly cou-
ples to the TGF-β signaling system by interacting physically
with TβR-II (Figure 2), resulting in enhanced MEC proliferation,
invasion, and EMT when stimulated with TGF-β (Figure 5).
More importantly, β3 integrin promotes Src mediated tyrosine
phosphorylation of TβR-II (Figure 6), which we show to be
essential for the ability of TGF-β to activate MAPKs (Figure 8)
and, consequently, to induce EMT in MECs (Figure 8). More
importantly, we show for the first time that induction of β3
integrin expression during mammary tumorigenesis correlates
with metastasis development, and that antagonizing β3 integrin
signaling abolishes TGF-β stimulation of breast cancer cell
invasion (Figure 9). Collectively, we identified a potentially
important mechanism whereby β3 integrin expression selec-
tively facilitates TGF-β stimulation of MEC invasion and EMT.
The joint activation of integrin and RTK signaling systems is
essential for the positional control of cells. More importantly,
cell attachment to the ECM also determines the nature and
context of how cells interpret and respond to cytokine and
growth factor binding [52]. For instance, the ability of EGF and
platelet-derived growth factor receptors to stimulate fibroblast
migration requires RTK receptor association with integrins and
FAK [24]. Similarly, Scaffidi and coworkers [42] showed that
αvβ3 integrin bound TβR-II in lung fibroblasts, thereby enhanc-
ing fibroblast proliferation stimulated by TGF-β. Those authors
further speculated that the formation of αvβ3 integrin:TβR-II
complexes may exacerbate TGF-β mediated wound healing
and fibrotic reactions [42], processes reminiscent of the ability
of β3 integrin:TβR-II complexes to drive TGF-β stimulation of
EMT in MECs. Most recently, the adapter protein Dab2, which
mediates Smad2/3 activation by TβRs [57], was shown to par-
ticipate in TGF-β stimulated EMT by interacting with integrins
and preventing MEC apoptosis [58]. These findings, together
with those presented herein, indicate an important and under-
appreciated role for integrins in regulating cellular response to
TGF-β. Future studies in MECs must determine the relation-
ship between TGF-β stimulated expression of β3 integrin and
Dab2, as well as β3 integrin stimulated TβR-II expression in
MECs; whether Dab2 links β3 integrin to TβR-II during EMT;
and the ability of additional integrins to influence, either posi-
tively or negatively, MEC response to TGF-β.
A particularly novel finding of our study was the demonstration
that β3 integrin induced TβR-II tyrosine phosphorylation via Src
kinase. Indeed, we show for the first time that Src activity medi-
ates tyrosine phosphorylation of TβR-II in MECs, leading to
TGF-β mediated MAPK activation, and to MEC invasion and
EMT. Previous studies established that TβR-II is phosphor-
ylated predominantly on Ser and Thr residues [8,13,59],
which, depending on the site of phosphorylation, either aug-
ments or attenuates TβR-II protein kinase activity [60]. How-
ever, tyrosine phosphorylation of TβR-II is not without
precedent. Indeed, Lawler and coworkers [61] showed that
TβR-II is a dual-specificity protein kinase that autophosphor-
ylates not only on Ser/Thr residues but also on tyrosine 259,
336, and 424. Moreover, although Phe substitution at these
positions significantly reduced TβR-II protein kinase activity,
these mutations had little affect on the ability of TGF-β to
induce gene expression in lung epithelial cells [61], and as
such the role of tyrosines 259, 336, and 424 in mediating
TGF-β action remain to be clarified. We too have converted
tyrosines 259, 336, and 424 to phenylalanine in all possible
combinations (i.e. single, double, and triple mutations), all of
which failed to alter Src mediated tyrosine phosphorylation of
GST-TβR-II (K277R) in vitro (Galliher AJ, Schiemann WP,
unpublished data). Sequence analysis of the cytoplasmic
domain of TβR-II revealed two possible Src phosphorylation
consensus motifs at tyrosines 284 and 470. These two sites
were individually mutated to phenylalanines, and preliminary
data suggest that Src phosphorylates TβR-II at tyrosine 284
(Galliher AJ, Schiemann WP, unpublished data). Further anal-Breast Cancer Research    Vol 8 No 4    Galliher and Schiemann 
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ysis of this site in mediating TGF-β stimulation of EMT in MECs
is currently under investigation.
Activation of MAPKs, particularly that of ERK1/2 [5] and p38
MAPK [2,32], are necessary for TGF-β to stimulate EMT. We
also found that TGF-β stimulation of ERK1/2 and p38 MAPK
are necessary for induction of EMT in MECs. More importantly,
we show for the first time that Src activity is essential for acti-
vation of MAPKs by TGF-β and for its stimulation of EMT.
Indeed, our results indicate that β3 integrin expression and Src
activity are sufficient in overcoming TGF-β mediated cytosta-
sis in MECs. Src activity also has been associated with pro-
tecting hepatocytes from apoptosis induced by TGF-β [62-64]
and with the ability of TGF-β to stimulate ovarian cancer cell
invasion [65]. More recently, TGF-β treatment of MECs was
shown to induce their expression of RPTPκ, a protein tyrosine
phosphatase that activates Src and mediates the antiprolifer-
ative and the promigratory effects of TGF-β [66]. These find-
ings, together with those presented herein, implicate Src as an
important player operant in dictating the MEC response to
TGF-β; they also suggest that Src inhibition, similar to integrin
interdiction, may one day be used to enhance the tumor sup-
pressing activities of TGF-β in breast cancer cells.
Finally, based on the fact that phosphotyrosine residues often
create binding motifs that couple receptors to various signal-
ing pathways [67], including the MAPK cascade, it is tempting
to speculate that Src-mediated tyrosine phosphorylation of
TβR-II functions similarly as a receptor docking site to recruit
SH2 and/or PTB containing signaling molecules to β3
integrin:TβR-II complexes. If correct, then such a mechanism
could account for the augmented ability of TGF-β to activate
MAPKs in β3 integrin expressing MECs, and for the shift in
MAPK and Smad2/3 signaling that favored EMT over cytosta-
sis in response to TGF-β. Indeed, the ability of β3 integrin to
increase Smad2/3 transcriptional activity without altering
Smad2/3 phosphorylation suggests that other integrin or
MAPK stimulated nuclear factors converge on TGF-β targeted
promoters and synergize with Smad2/3 in coordinating gene
expression regulated by TGF-β. This notion is wholly consist-
ent with previous work demonstrating the ability of Smad2/3
to synergize with activated TβR complexes in mediating EMT
[37,68].
Conclusion
In summary, we present evidence that the differential expres-
sion of β3 integrin induced by TGF-β functions to convert this
cytokine from an inhibitor of MEC proliferation to a stimulator
of their EMT and invasion. More importantly, we show that β3
integrin regulates TGF-β signaling by interacting physically
with TβR-II and stimulating its phosphorylation on tyrosine res-
idues by Src. The net effect of these events results in
enhanced TGF-β stimulation of MAPKs and, consequently,
induction of EMT and invasion in MECs. Indeed, our findings
suggest that integrin interdiction may prevent tumor develop-
ment and progression by maintaining, reinforcing, or re-estab-
lishing the tumor suppressing activities of TGF-β.
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